Full Press Release Details
INmune Bio to Present XPro1595
for Treating Neuroinflammation in Alzheimer's Disease at 2019 Alzheimer's Association International Conference (AAIC)
LA JOLLA, Calif., Sept. 23,
2019 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), an immunotherapy company developing treatments which harness the patient's
innate immune system to fight disease, announced today that the company will be presenting at the upcoming Alzheimer's Association
International Conference (AAIC) Satellite Symposium held Sept. 25 - 27 in Sydney, Australia.
C.J. Barnum, Ph.D., Director
of Neuroscience at INmune Bio, will present the company's strategy for treating Alzheimer's disease at a panel session,
along with other global researchers and leaders in the latest therapeutics and developments in Alzheimer's clinical research.
"Neuroinflammation is
now widely recognized as a key therapeutic target in Alzheimer's disease," said Dr. Barnum. " We believe that
neuroinflammation plays a critical role in neurologic disorders like Alzheimer's and our drug candidate, XPro1595 is starting
clinical trials to test this hypothesis."
AAIC is the premier annual
conference for presentation and discussion of the latest Alzheimer's and dementia research. The AAIC Satellite Symposium
is part of the events organized by the Alzheimer's Association and gathers researchers from around the world to discuss
scientific advances in the understanding and treatment of Alzheimer's disease and other related dementias. Dr. Barnum will
present during a panel session moderated by Mal Tansey, Ph.D., Professor of Neuroscience and Director of the Center for
Translational Research in Neurodegenerative Disease at the University of Florida College of Medicine.
Session 3: Therapeutics:
Presentation Title: A
Biomarker-Directed Approach to Targeting Inflammation in Alzheimer's Patients
PM - 5:30 PM, Sept. 25
Regency Sydney, Australia
Alzheimer's disease is
a progressive neurodegenerative disease that is the most common cause of dementia and is characterized by the decline in cognitive
function and neuronal loss. Sustained activation of the brain's resident macrophages (microglia) and other immune cells
have emerged as the underlying pathological condition that facilitates and exacerbates the progression of the disease. For more
information about the importance of targeting neuroinflammation in the brain to improve cognitive function and restore neuronal
communication visit this section of the INmune Bio's website.
About the Alzheimer's
The Alzheimer's Association
is the leading voluntary health organization in Alzheimer's care, support and research. Its mission is to eliminate Alzheimer's
disease through the advancement of research; to provide and enhance care and support for all affected, and to reduce the risk
of dementia through the promotion of brain health. Its vision is a world without Alzheimer's. Visit the Alzheimer's
Association website or call 800.272.3900.
About INmune Bio, Inc.
INmune Bio, Inc. is a publicly
traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system
to fight disease. INmune Bio has two product platforms. The DN-TNF product platform utilizes dominant-negative technology
to selectively neutralize soluble TNF, a key driver of innate immune dyfunction and mechanistic target of many diseases. DN-TNF
is currently being developed for cancer (INB03), Alzheimers (XPro595), and NASH (NeuLiv). The Innate Immune Priming Platform includes
INKmune aimed at priming the patient's NK cells to eliminate minimal residual disease in patients with cancer. INmune
Bio's product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic malignancies,
solid tumors and chronic inflammation. To learn more, please visit www.inmunebio.com.
Forward-Looking Statements
Any statements contained in
this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in
the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations
but are subject to a number of risks and uncertainties. Actual results and the timing of certain events and circumstances may
differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. INBO3 and
XPro1595 are still in clinical trials and have not been approved and there cannot be any assurance that they will be approved.
The factors that could cause actual future results to differ materially from current expectations include, but are not limited
to, risks and uncertainties relating to the Company's ability to produce more drug for clinical trials; the availability
of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical
studies and future product commercialization; and, the Company's business, research, product development, regulatory approval,
marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company's
filings with the Securities and Exchange Commission, including the Company's Annual Report on Form 10-K for the year ended
December 31, 2018, the Company's Quarterly Reports on Form 10-Q and the Company's Current Reports on Form 8-K. The
Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may
arise after the date of this release.